Lymphoma, T-Cell Clinical Trial
Official title:
Early Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.
Main research purposes: To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies. Secondary research purposes: To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory CD7+ hemolymphoid malignancies. Exploratory research purpose： 1. To explore the immunogenicity of SENL101； 2. T cell NK cell recovery time after treatment； 3. Other indicators of interest to researchers。 ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
| Completed |
NCT02158975 -
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
|
Phase 2 | |
| Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
| Completed |
NCT00069238 -
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03703375 -
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
|
Phase 3 | |
| Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00038376 -
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
|
Phase 2 | |
| Recruiting |
NCT03161223 -
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03902184 -
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
| Completed |
NCT04121507 -
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
|
Phase 2 | |
| Completed |
NCT04136275 -
CAR-37 T Cells In Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03921879 -
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
|
Phase 1 | |
| Terminated |
NCT03154710 -
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
|
N/A | |
| Recruiting |
NCT05466318 -
ChiCGB vs BEAM in High-risk or R/R Lymphomas
|
Phase 3 | |
| Recruiting |
NCT04928105 -
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
|
N/A | |
| Withdrawn |
NCT04233697 -
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT01309789 -
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
|
Phase 1 | |
| Recruiting |
NCT05557903 -
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
|
Phase 1 |